- BGI Publishes Largest Ever Genomic Study of Chinese Population Discoveries in more than 140,000 Genomes throughout China
- BGI, NOAA Fisheries, and The Nature Conservancy Announce Partnership to Help Endangered Orcas
- BGI Signs Memorandum of Understanding with The University of Michigan
- China National GeneBank Signs a Colleboration Agreement with Queensland University on Scientific Research
- Establishment of the first Macaca fascicularis gut microbiome gene catalog
- Establishing the first gene catalogue of Sprague-Dawley rat gut metagenome based on the BGISEQ-500 platform
- The international Sc2.0 Project is on track to build the world’s first synthetic yeast genome
- Avian-specific conserved genomic elements play important regulatory roles in the macroevolution of avian-specific features
- Leading Health Organizations in Canada and China Teaming up to Accelerate Precision Medicine
- World’s largest genomic organisation to collaborate with leading Queensland researchers
- Ranomics Partners with BGI to Classify Variants of Unknown Significance
- BGI and UW collaborate on precision medicine development
- Meet The Chinese Company That Wants To Be The Intel Of Personalized Medicine
- Chinese innovation : BGI’s code for success
- Prof. Huanming Yang to Receive Membership from Royal Danish Academy of Sciences and Letters
- UW, Chinese genomics group forge new partnership to advance biomedical research
Tel: +86-755-36307212Email: email@example.com
November 5, 2016, Shenzhen, China—BGI today launched its latest high-throughput sequencing platform, BGISEQ-50, at the 11th International Conference on Genomics (ICG-11). It is a miniaturized sequencer that after BGISEQ-500 to continue to reinforce the NGS (Next Generation Sequencing).
Based on the technique from combinatorial Probe-Anchor Synthesis (cPAS) and DNA Nanoballs (DNB) sequencing, BGISEQ-50 is a sharp, dedicated and smart high-throughput sequencing platform. It adopts high precision parts and has a built-in independent sample reagent loading reservoir and full-automatic reagent needle penetration system. The simplified structure can realize multiple automatic functions, including sample loading, sequencing and data analyzing. The compact size makes it easier to be placed. It has specific applicability for basic sequencing projects in clinical and scientific research. Furthermore, it accommodates operation even under low-pressure environment at high altitude.
BGISEQ-50 adopts intelligent, touch-sensitive interface, providing compatible function of full-automatic sample tracking management, and offers the optimal process guidance. The sequencing is simple to operate: respectively place the pre-built integrated sequencing reagent box and micromachined sequencing chip into the device and click "sequencing" button to start a 10-hour automatic sample loading and sequencing. Unattended mode is supported and data analysis is achieved in a single step. The whole process including sample preparation can be completed in 18 hours with the optional automatic sample preparation system.
At the product launch, BGI demonstrated the applications of BGISEQ-50 on Non-Invasive Prenatal Screening (NIPS), Preimplantation Genetic Screening (PGS), Chromosome abnormality Sequencing (ChromoSeq), Pathogens Detection (PM-Seq), RNA-Seq and others. The system can finish 16 NIPT tests per run and with the capacity of over 10,000 tests per year at more affordable and accessible cost.
Duncan Yu, COO of BGI, noted: “The BGISEQ-50 is a miniaturized desktop sequencer designed to provide rapid and efficient sequencing solutions and to advance precision medicine, personalized healthcare and even digitize life.” BGISEQ-50 will be available in China first and starts to take order by the end of this year with delivery begin in early 2017.
On October 24, 2015, BGI released its new desktop sequencing system, BGISEQ-500, at the 10th International Conference on Genomics (ICG-10). As the first sequencer supporting volume production in China, BGISEQ-500 has received more than 500 orders and completed more than 112,000 tests since the end of 2015, including over 20,000 RNA-seq samples.
In October 2016, the China Food and Drug Administration (CFDA) approved the registration of BGISEQ-500 for medical device, allowing BGISEQ-500 to provide more cost-effective and advanced applications in clinical genetic sequencing.
“BGI aims to provide an open platform to develop more applications with our global partners, to provide more targeted, more applicable, more convenient and more affordable genetic testing services and products for the general public, and strive to achieve the vision of BGI - ‘Trans-omics for a better life’.” Feng Mu, Vice President of BGI said in a statement.